VANCOUVER, BC--(Marketwired - February 18, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO Europe in Paris, France, on March 11th at 11:30AM GMT at the Paris Expo - Porte de Versailles.

The presentation will include safety and efficacy results of the new skin lightener TFC-1067, the glycoprotein program for anti-aging and regenerative medicine, as well as updates from the SGLT2 inhibitor program that is currently under license agreement with Wanbang Biopharmaceuticals -- headquartered in the People's Republic of China. All results will be released publicly prior to the presentation.

Major companies attending the conference include Johnson & Johnson, GSK, Pfizer and many others. Sirona Biochem Senior Management will be attending other international partnering meetings and events in the near future as the company continues its business objective of licensing its world class platform technology.

About BIO Europe

BIO-Europe Spring® is the springtime counterpart to EBD Group's flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities.

BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants.

For more information please visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

For more information regarding this press release, contact:

Christopher Hopton
Sirona Biochem Corp.
Phone: 1.604.282.6064